Boston Scientific Corporation

Boston Scientific Corporation is an American medical device company that develops, manufactures, and markets devices used in interventional cardiology, electrophysiology, cardiac rhythm management, endoscopy, urology, and neuromodulation, generating $20.1 billion in revenue in fiscal 2025. Headquartered in Marlborough, Massachusetts, the company employs approximately 59,000 people and sells its products in 127 countries.

This is a story about a medtech compounder hitting an air pocket. For three years, Boston Scientific delivered the kind of growth that makes competitors envious — 16% organic revenue growth in 2025, 22% adjusted EPS growth — powered by two extraordinary franchises: FARAPULSE, the pulsed-field ablation system that reshaped the electrophysiology market, and WATCHMAN, the left atrial appendage closure device that created a new standard of care in stroke prevention. Those two businesses carried the company past $20 billion in revenue and funded investments across the portfolio. Now, in mid-2026, both are decelerating, and management's Q2 2026 guidance cut tells you the slowdown arrived faster than they expected.

The file turns on a single question: whether the rest of Boston Scientific's portfolio — Interventional Cardiology and Vascular Therapies, Neuromodulation, Endoscopy, and the pending $14.5 billion Penumbra acquisition — can generate enough growth to bridge the gap between now and the next wave of pipeline launches in 2027–2028, without the balance sheet or the earnings multiple buckling under the weight of $11 billion in new debt.